BRIEF-Guardant Health Announced the results of the Serena-6 Phase III Trial

Reuters
02 Jun
BRIEF-Guardant Health Announced the results of the Serena-6 Phase III Trial

June 2 (Reuters) - Guardant Health Inc GH.O:

  • SERENA-6 PHASE III TRIAL DEMONSTRATES CLINICAL VALUE OF GUARDANT360 CDX TEST TO DETECT EMERGENCE OF ENDOCRINE RESISTANCE AND INFORM A SWITCH IN THERAPY BEFORE RADIOLOGICAL DISEASE PROGRESSION IN ADVANCED BREAST CANCER

Source text: ID:nBwMTNgRa

Further company coverage: GH.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10